Connect Biopharma Announces Participation in Investor Conferences
Connect Biopharma Set to Engage Investors at Key Conferences
Connect Biopharma Holdings Limited (Nasdaq: CNTB), a pioneering clinical-stage biopharmaceutical company dedicated to improving the treatment of inflammatory diseases, has exciting news for investors. The management team is gearing up to present at two significant investor conferences. These events provide an excellent platform for those interested to learn more about the company's innovative advancements and clinical pipeline.
Details of Upcoming Conferences
Cantor Global Healthcare Conference 2025
This conference will feature a Fireside Chat where Connect Biopharma will share insights about its ongoing projects and future directions. The session is scheduled for Wednesday at 3:20 p.m. ET, and interested parties can register for the event online.
H.C. Wainwright Annual Global Investment Conference
On Monday, Connect Biopharma will also be a part of the H.C. Wainwright 27th Annual Global Investment Conference, with a Fireside Chat starting at 9:30 a.m. ET. This session is another opportunity for investors to gain valuable information about the company's growth trajectory and product developments.
Accessing the Presentations
For those who cannot attend, live webcasts of the presentations will be made available on the Connect Biopharma website in the Investors section. The replays of both events will also be accessible for about 90 days after the conferences, allowing broader access to meaningful discussions.
About Connect Biopharma
Connect Biopharma is committed to transforming the treatment landscape for conditions such as asthma and chronic obstructive pulmonary disease (COPD). The company is currently advancing its lead product candidate, rademikibart, an innovative antibody designed to effectively target IL-4R?. By focusing on areas with substantial unmet medical needs, Connect Biopharma has embarked on critical global clinical studies aimed at addressing acute asthma and COPD exacerbations. Moreover, the company has established an exclusive partnership for rademikibart with Simcere in China, which showcases its dedication to expanding market reach and enhancing patient care globally.
Investor Relations
For further inquiries regarding Connect Biopharma’s progress and future plans, investors can reach out to Alex Lobo from Precision AQ, who is available for questions at (212) 698-8802 or via email.
Frequently Asked Questions
What is the focus of Connect Biopharma?
Connect Biopharma specializes in developing treatments for inflammatory diseases, particularly addressing asthma and COPD.
What product is Connect Biopharma currently advancing?
The company is advancing rademikibart, a next-generation antibody targeting IL-4R? for treating asthma and COPD.
How can investors attend the upcoming conferences?
Investors can register for the Cantor Global Healthcare Conference and H.C. Wainwright Conference through links available on the Connect Biopharma website.
Where can presentation replays be accessed?
Archived replays of the conference presentations will be available on the Investors section of the Connect Biopharma website for approximately 90 days following the events.
Who should investors contact for more information?
Investors can contact Alex Lobo for investor relations inquiries at Precision AQ for further details and updates.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.